Skip to main content
SpringerLink
Log in

Vinflunine (20′,20′-difluoro- 3′,4′-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Vinflunine (VFL) is a novel derivative of vinorelbine (NVB, Navelbine®), which has shown markedly superior antitumor activity to NVB, in various experimental animal models. To establish whether this new Vinca alkaloid participates in P-glycoprotein (Pgp)-mediated multidrug resistance (MDR), VFL-resistant murine P388 cells (P388/VFL) were established in vivo and used in conjunction with the well established MDR P388/ADR subline, to define the in vivo resistance profile for VFL. P388/VFL cells proved cross-resistant to drugs implicated in MDR (other Vinca alkaloids, doxorubicin, etoposide), but not to campothecin or cisplatin and showed an increased expression of Pgp, without any detectable alterations in topoisomerase II or in glutathione metabolism. The P388/ADR cells proved cross-resistant to VFL both in vivo and in vitro, and this VFL resistance was efficiently modulated by verapamil in vitro. Cellular transport experiments with tritiated-VFL revealed differential uptake by P388 sensitive and P388/ADR resistant cells, comparable with data obtained using tritiated-NVB. In various in vitro models of human MDR tumor cells, whilst full sensitivity was retained in cells expressing alternative non-Pgp-mediated MDR mechanisms, cross resistance was identified in Pgp-overexpressing cells. Differences were, however, noted in terms of the drug resistance profiles relative to the other Vincas, with tumor cell lines proving generally least cross-resistant to VFL. Overall, these results suggest that VFL, like other Vinca alkaloids, participates in Pgp-mediated MDR, with tumor cells selected for resistance to VFL overexpressing Pgp, yet MDR tumor cell lines proved generally less cross resistant to VFL relative to the other Vinca alkaloids.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kruczynski A, Colpaert F, Tarayre JP, Mouillard P, Fahy J, Hill BT: Preclinical in vivoantitumour activity of vinflumine, a novel fluorinated Vincaalkaloid. Cancer Chemother Pharmacol 41:437-447, 1998

    Google Scholar 

  2. Kruczynski A, Barret JM, Etievant C, Colpaert F, Fahy I, Hill BT: Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vincaalkaloid. Biochem Pharmacol 55:635-648, 1998

    Google Scholar 

  3. Pastan I, Gottesman MM: Multidrug resistance. Annu Rev Med 42:277-286, 1991

    Google Scholar 

  4. Hill BT: Differing patterns of cross-resistance resulting from exposure to specific antitumour drugs or to radiation in vitro. Cytotechnology 12:265-288, 1993

    Google Scholar 

  5. Hill BT, Whelan RD, Shellard SA, McLean S, Hosking L: Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs 12:169-182, 1994

    Google Scholar 

  6. Beck WT: Mechanisms of multidrug resistance in human tumor cells). The roles of P-glycoprotein, DNA topoisomerase II, and other factors. Cancer Treat Rev 17:11-20, 1990

    Google Scholar 

  7. Murren JR, Hait WN: Why haven't we cured multidrug resistant tumors? Oncol Res 4:1-6, 1992

    Google Scholar 

  8. Aftab DT, Yang JM, Hait WN: Functional role of phosphorylation of the multidrug transporter (P-glycoprotein) by protein kinase C in multidrug resistant MCF-7 cells. Oncol Res 26:69-70, 1994

    Google Scholar 

  9. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Med 62:385-427, 1993

    Google Scholar 

  10. Pinedo HM: Drug resistance, illustration of the complexity of translational research. Steiner Award Lecture. Int J Cancer 65:561-566, 1996

    Google Scholar 

  11. Mirski SE, Gerlach JH, Cole SPC: Multidrug resistance in a human small cell lung cancer cell line selected in Adriamycin. Cancer Res 47:2594-2598, 1987

    Google Scholar 

  12. Cole SPC, Chanda ER, Dicke FP, Gerlach JH, Mirski SE: Non-P-glycoprotein-mediated multidrug resistance in a small cell lung carcinoma cell line: Evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res 51:3345-3352, 1991

    Google Scholar 

  13. Cole SPC, Bhardwaj G, Gerlach JH, Machie JE, Grant CE, Almquist KC, Stewart AJ, Kurts EU, Duncan AMV, Deeley RG: Overexpression of a transporter gene in a multi-drugresistant human lung cancer cell line. Science 258:1650-1654, 1992

    Google Scholar 

  14. Zaman GJR, Versantwoort CHM, Smit JJM, Eijdems EWHM, de Haas M, Smith AJ, Broxterman HJ, Mudler NH, de Vries EGE, Baas F, Borst P: Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant cancer cell lines. Cancer Res 53:1747-1750, 1993

    Google Scholar 

  15. Barrand MA, Heppell-Parton AC, Wright KA, Rabbitts PH, Twentyman PR: A 190-kilodalton protein overexpressed in non-P-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene. J Natl Cancer Inst 86:110- 117, 1994

    Google Scholar 

  16. Adams DJ, Knick VC: P-glycoprotein mediated resistance to (5'-nor-anhydro-vinblastine (Navelbiner®). Invest New Drugs 13:13-21, 1995

    Google Scholar 

  17. Fahy J, Duflos A, Ribet JP, Jacquesy JC, Berrier C, Jouannetaud MP, Zunino F: Vinca-alkaloids in superacidic media: a method for creating a new family of antitumor derivatives. J Am Chem Soc 119:8576-8577, 1997

    Google Scholar 

  18. Workman P, Balmain A, Hickman JA, McNally NJ, Rohas AM, Mitchison NA, Pierrepoint CG, Raymond R, Rowlatt C, Stephens TC, Wallace J, Straughan DW: UKCCCR guidelines for the welfare of animals in experimental neoplasia. Laboratory Animals 22:195-201, 1988

    Google Scholar 

  19. Venditti JM: Preclinical drug development; rationale and methods. Semin Oncol 8:349-361, 1981

    Google Scholar 

  20. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685, 1970

    Google Scholar 

  21. Habig WH, Pabst MJ, Jakoby WB: Glutathione S-transferases. J Biol Chem 219:7130-7139, 1974

    Google Scholar 

  22. Griffith OW: Determination of glutathione and glutathione disulfide using glutathione reductase and 2 vinyl pyridine. Anal Biochem 106:207-212, 1980

    Google Scholar 

  23. Bradford MM: A rapid and sensitive method for the quantifcation of microgram quantity of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254, 1976

    Google Scholar 

  24. Johnson RK, Chitnis MP, Embrey WM, Gregory EB: In vivocharacteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia. Cancer Treat Rep 62:1535-1547, 1978

    Google Scholar 

  25. Kartner N, Everden-Porelle D, Bradley G, Ling V: Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316:820-823, 1985

    Google Scholar 

  26. Danks MK, Schmidt CA, Cirtain MC, Suttle DP, Beck WT: Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from leukemic cells selected for resistance to VM-26. Biochemistry 27:8861-8869, 1988

    Google Scholar 

  27. Cowan KH, Batist G, Tulpule A, Sinha B, Myers CE: Similar biochemical changes in human breast cancer cells and carcinogen-induced resistance to xenobiotics. Proc Natl Acad Sci USA 83:9328-9332, 1986

    Google Scholar 

  28. Pauwels O, Kiss R: Digital morphnuclear analysis of sensitive versusresistant neoplastic cells to Vinca-alkaloid, alkylating, and intercalating drugs. Cytometry 12:388-397, 1991

    Google Scholar 

  29. De Jong S, Zijlstra JG, de Vries EGG, Mudler NH: Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in extracts from a human small cell lung carcinoma cell line. Cancer Res 50:304-309, 1990

    Google Scholar 

  30. Kamath N, Grabowski D, Ford J, Kerrigan D, Pommier Y, Ganapathi R: Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivofor resistance to mitoxantrone. Biochem Pharmacol 44:937-945, 1992

    Google Scholar 

  31. Chen G, Waxman DJ: Complete reversal by Thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells). Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug-resistance. J Pharmacol Expt Therapeut 274:1271-1277, 1995

    Google Scholar 

  32. Labarre JF: Natural polyamines-linked cyclophosphazenes: attempts at the production of more selective antitumourals. Topic Curr Chem 129:173-260, 1985

    Google Scholar 

  33. Etievant C, Pauwels O, Kiss R: Digital cell image analysis of verapamil-induced effects in chemosensitive and chemoresistant neoplastic cell lines. J Cancer Res Clin Oncol 120:76-84, 1993

    Google Scholar 

  34. Hipfner D, Gauldie SD, Deeley RG, Cole SPC: Detection of the Mr 190,000multidrug resistance protein, MRP, with monoclonal antibodies. Cancer Res 54:5788-5792, 1994

    Google Scholar 

  35. Versantvoort CHM, Withoff S, Broxterman HJ, Kuiper CM, Scheper RJ, Mulder NH, de Vries EGE: Resistance-associated factors in human small-cell lung-carcinoma GLC4 sub-lines with increasing adriamycin resistance. Int J Cancer 61:375- 380, 1995

    Google Scholar 

  36. Mosman T: Rapid colorimetric assay for cellular growth and survival: atapplication to proliferation and cytotoxicity assays. J Immunol Method 65:55-63, 1983

    Google Scholar 

  37. Kramer RA, Zakher J, Kim G: Role of the glutathione redox cycle in acquired and de novomultidrug resistance. Science 241:694-697, 1988

    Google Scholar 

  38. Deffie AM, Alam T, Seneviratne C, Beenken SW, Batra JK, Shea TC, Henner WD, Goldenberg GJ: Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux and P-glycoprotein in cloned cell lines of adriamycin-sensitive and-resistant P388 leukemia. Cancer Res 48:3595-3602, 1988

    Google Scholar 

  39. Ford JM: Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Eur J Cancer 32A:991-1001, 1996

    Google Scholar 

  40. Creasey WA, Markiw MM: Biochemical effects of the Vincaalkaloids III). The synthesis of ribonucleic acid and the incorporation of amino acids in Ehrlich ascites cells in vitro. Biochim Biophys Acta 103:635-645, 1965

    Google Scholar 

  41. Owellen RJ, Donigian DW, Hartke CA, Hains FO: Correlation of biologic data with physicochemical properties among the Vincaalkaloids and their congeners. Biochem Pharmacol 26:1213-1219, 1977

    Google Scholar 

  42. Vendrik CPJ, Bergers JJ, De Jong WH, Steerenberg PA: Resistance to cytostatic drugs at the cellular level. Cancer Chemother Pharmacol 29:413-429, 1992

    Google Scholar 

  43. Fichtner I, Stein U, Hoffmann J, Winterfield G, Pfeil D, Hentschel M: Characterization of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance and proliferation-markers, immunogenicity. Anticancer Res 14:1995-2004, 1994

    Google Scholar 

  44. Tang-Wai DF, Brossi A, Arnold LD, Gros P: The nitrogen of the acetamido group of cochicine modulates P-glycoprotein-mediated multidrug resistance. Biochemistry 32:6470-6476, 1993

    Google Scholar 

  45. Ringel I, Jaffe D, Alerhand S, Boye O, Muzaffar A, Brossi A: Fluorinated colchicinoids: antitubulin and cytotoxic properties. J Med Chem 34:3334-3338, 1991

    Google Scholar 

  46. Judson I, Briasoulis E, Raynaud F, Hanwell J, Berry C, Lacey H: Phase I trial and pharmacokinetics of the tubulin inhibitor 1069C85 - a synthetic agent binding at the cochicine site designed to overcome multidrug resistance. Br J Cancer 75(4):608-613, 1997

    Google Scholar 

  47. Rowinsky EK, Long GS, Noe DA, Grochow LB, Bowling MK, Sartorius SE, Donehower RC: Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent. Clin Cancer Res 3:401-407, 1997

    Google Scholar 

  48. Inaba M, Fujikura R, Sakurai Y: Comparative study on in vivodevelopment of resistance to various classes of antitumor agents in P388 leukemia. Gann 70:607-613, 1979

    Google Scholar 

  49. Hill BTH, Whelan RDH: Establishment of vincristine-resistant and vindesine-resistant lines of murine lymphoblasts in vitroand characterization of their patterns of cross-resistance and drug sensitivities. Cancer Chemother Pharmacol 8:163-169, 1982

    Google Scholar 

  50. Nielsen D, Skovsgaard T: P-glycoprotein as multidrug transporter: a critical review of current multidrug resistant cell lines. Biochim Biophys Acta 1139:169-183, 1992

    Google Scholar 

  51. Kaye SB: Reversal of multidrug resistance. Cancer Treat Rev 18:37-43, 1990

    Google Scholar 

  52. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE: P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9:17-24, 1994

    Google Scholar 

  53. Tsuruo T, Tomida A: Multidrug resistance. Anti-Cancer Drugs 6:213-218, 1995

    Google Scholar 

  54. Lautier D, Canitrot Y, Deeley RG, Cole SPC: Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol 52:967-977, 1996

    Google Scholar 

  55. Zaman GJR, Lankelma J, van Tellingen O, Beijnen J, Dekker H, Paulusma C, Oude Elferink RPJ, Baas F, Brost P: Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc Nat Acad Sci USA 92:7690-7694, 1995

    Google Scholar 

  56. Loe DW, Almquist KC, Deeley RG, Cole SPC: Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicules: demonstration of glutathione-dependent vincristine transport. J Biol Chem 271:9675-9682, 1996

    Google Scholar 

  57. Dhar S, Nygren P, Csoka K, Botling J, Nilsson K, Larsson R: Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. Br J Cancer 74:888-896, 1996

    Google Scholar 

  58. Gottesman MM: How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal foundation award lecture. Cancer Res 53:747-754, 1993

    Google Scholar 

  59. Colin M, Madoulet C, Warren L, Jardillier JC: Alterations of vinblastine influx in multidrug-resistant lymphoblastic leukaemic CEM cells. Anticancer Res 16:407-412, 1996

    Google Scholar 

  60. Zhou XJ, Rhamani R: Preclinical and clinical pharmacology of Vincaalkaloids. Drugs 44:1-16, 1992

    Google Scholar 

  61. Houghton JA, Houghton PJ, Hazelton BJ, Douglas EC: In situselection of a human rhabdomyosarcoma resistant to vincristine with altered β-tubulins. Cancer Res 45:2706-2712, 1985

    Google Scholar 

  62. Cabral F, Barlow SB: Mechanisms by which mammalian cells acquire resistance to drugs that affect microtubule assembly. FASEB J 3:1593-1599, 1989

    Google Scholar 

  63. Jafrézou JP, Dumontet C, Derry WB, Duran G, Chen G, Tsuchiya E, Wilson L, Jordan MA, Sisik BI: Novel mechanism of resistance to paclitaxel (Taxol®) in human K562 leukemia cells by combined selection with PSC 833. Oncology Res 7:517-527, 1995

    Google Scholar 

  64. Hickman JA: Apoptosis and chemotherapy resistance. Eur J Cancer 32A:921-926, 1996

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division de Cancerologie Experimentale I, Centre de Recherche Pierre Fabre, Castres, France

    Chantal Etievant, Jean-Marc Barret, Anna Kruczynski, Dominique Perrin & Bridget T. Hill

Authors
  1. Chantal Etievant
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean-Marc Barret
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anna Kruczynski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dominique Perrin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bridget T. Hill
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Etievant, C., Barret, JM., Kruczynski, A. et al. Vinflunine (20′,20′-difluoro- 3′,4′-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro. Invest New Drugs 16, 3–17 (1998). https://doi.org/10.1023/A:1006022811895

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006022811895

Search

Navigation